# Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

> **NCT03353350** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 406 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** efpeglenatide (SAR439977)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03353350
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-05
- **Primary completion:** 2020-01-29
- **Final completion:** 2020-09-07
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2022-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353350, "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03353350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*